Side-by-side comparison of AI visibility scores, market position, and capabilities
Greenwood Village CO YC W20 clinical biotech (NASDAQ: VRDN) with $636.6M cash; veligrotug BLA submission H2 2025 for thyroid eye disease competing with Tepezza; FcRn inhibitor platform with VRDN-003 and VRDN-006 in development.
Viridian Therapeutics is a Greenwood Village, Colorado-based clinical-stage biotechnology company — backed by Y Combinator (W20) and publicly traded on NASDAQ (VRDN) — developing FcRn inhibitor therapies for thyroid eye disease (TED) and other serious rare diseases driven by IgG autoantibodies. Maintaining $636.6 million in cash and short-term investments as of March 2025 (sufficient to fund operations into the second half of 2027), Viridian is advancing veligrotug (subcutaneous FcRn inhibitor, BLA submission expected H2 2025 for TED, MAA to EMA expected H1 2026), VRDN-003 (topline clinical data expected H1 2026), and VRDN-006 (proof-of-concept data expected Q3 2025), with $86.6 million in R&D expenses in Q2 2025 reflecting accelerated clinical development investment.
Llama 4 open-source model (Scout, Maverick, Behemoth) released March 2026; Meta AI assistant deployed to 700M+ users across WhatsApp, Instagram, Facebook. FAIR research driving multimodal AI advances; $35B AI capex in 2025.
Meta Platforms is a Menlo Park, California-based technology conglomerate operating the world's most widely used social media ecosystem — Facebook (3+ billion monthly active users), Instagram (2+ billion MAU), WhatsApp (2.8+ billion MAU), and Threads (launched 2023) — while investing heavily in virtual reality hardware (Meta Quest), augmented reality glasses (Meta Ray-Ban, Orion AR glasses in development), and AI research (Llama open-source model family). Listed on NASDAQ (NASDAQ: META), Meta generated $164.5 billion in revenue in fiscal year 2024 and employs approximately 74,000 people globally.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.